Comparing Dapagliflozin and Glimepiride in treating patients with type 2 Diabetes.

Phase 4

• Conditions: Type 2 Diabetes Mellitus.; Type 2 Diabetes; E11.9

• Registration Number: IRCT20220408054450N1
• Lead Sponsor: Bahria University Medical & Dental College

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

normal baseline levels of LFT, RFT, lipid profile, and white blood cell count (WBC).
The fasting plasma glucose (FBG) levels of all recruited participants to be = 126 mg/dL
hemoglobin A1c levels to be >7-10%
1500 mg/day metformin monotherapy for last 3 to 6 months.
Age of 45-55 years old
Either gender

Exclusion Criteria

Hypertension
Decompensated or acute congestive heart failure
Estimated glomerular filtration rate (egfr) less than 60 ml/min/1.73 m2
Left ventricular ejection fraction (levf) less than 40%
Liver impairment
Terminal illness, or cancer
Unwilling to give consent or participate

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemoglobin A1c (HbA1c) - Glycelated hemoglobin. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Levels were measured through blood samples using analyser in laboratory.;Fasting Plasma Glucose (FPG). Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Levels were measured through blood samples using device for plasma blood glucose.

Secondary Outcome Measures

Name	Time	Method
iver Function Test. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Renal Function Test (RFT). Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Lipid Profile. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Measured by taking samples from the patient.;Hypoglycemic Events. Timepoint: before intervention and 6, 12 weeks during intervention. Method of measurement: Through fasting Plasma glucose levels and medical history.